<DOC>
	<DOCNO>NCT00431522</DOCNO>
	<brief_summary>- To determine total local gray matter volume , N-acetyl aspartate ( NAA ) level patient bipolar disorder within euthimic , depressive manic/hypomanic period take drug ; - To investigate neuroprotective effect long-term ( 6 week ) use valproate total local gray matter volume NAA level . - To measure brain electrical response visual auditory impulse valproate treatment patient within euthimic , depressive manic/hypomanic period take drug , compare data normal group . - To determine cognitive function valproate treatment patient group , compare data age- sex-paired normal control ; - To determine relationship effect valproate clinical improvement ; - To investigate relationship cognitive ability status electrical activity brain , compare control group ; determine relationship data brain imaging ( MRI/MRS ) find conjunction localization</brief_summary>
	<brief_title>Valproic Acid Sodium Salt Bipolar Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>diagnosis type I II bipolar disorder accord DSMIV stratify SCID I interview , currently euthimic ( least one month ) , manichypomanic YMRS point 15 , depressive episode HAMD21 point 15 take drug least two week participate study ( except benzodiazepins ) female pregnant planning pregnant , nurse know hypersensitivity study drug give psychotropic agent benzodiazepine within last two week active sustance alcohol usage within last two week , substance addiction cafein nicotine ( within last month ) another axis I disorder comorbid dementia , delirium , obsessive compulsive disorder , eat disorder unstabilised hepatic renal disorder , thyroid blood disease history cerebral surgery existence degenerative neurologic disease epilepsy pacemaker prosthesis able magnetic effect eye , brain site near region homicide thougths severe catatonia require hospitalize mixed episode The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2009</verification_date>
</DOC>